Latest Breaking News On - Julia neugebauer - Page 17 : comparemela.com

Invitation to MorphoSys First Quarter 2023 Financial Results Conference Call on May 4, 2023

Invitation to MorphoSys First Quarter 2023 Financial Results Conference Call on May 4, 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesThomas biegiEamonn nolanJulia neugebauerExchange commissionMorphosy annual report

Invitation to MorphoSys First Quarter 2023 Financial Results Conference Call on May 4, 2023

EQS-News: MorphoSys AG / Key word: Quarter Results Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023 27.04.2023 / 22:03. | June 18, 2023

United statesJulia neugebauerThomas biegiEamonn nolanExchange commissionConference callMorphosy first quarterResults conference callMorphosy annual report

Invitation to MorphoSys First Quarter 2023 Financial Results Conference Call on May 4, 2023

Invitation to MorphoSys First Quarter 2023 Financial Results Conference Call on May 4, 2023
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United statesThomas biegiJulia neugebauerEamonn nolanDistribution servicesExchange commissionQuarter resultsMorphosy first quarterResults conference callMorphosy annual reportCorporate newsRegulatory announcements

Incyte and MorphoSys U S Inc : MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)

Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary

United statesUniversity hospitalSteven steinJohannes duellKaitlyn nealyJulia neugebauerChristine chiouThomas biegiJenifer antonacciTim demuthPublic affairsMorphosys us incAmerican association for cancer researchExchange commissionAmerican association for cancer research annual meetingPractice research clinical haematology

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUniversity hospitalChristine chiouJenifer antonacciTim demuthSteven steinJulia neugebauerJohannes duellKaitlyn nealyThomas biegiExchange commissionDrug administrationAmerican association for cancer research annual meetingPractice research clinical haematologyXencor incPublic affairs